Kert, Morley J.; Mailman, Richard H.; Roth, Samuel J.; Witherbee, Harold; Avedon, Melvin
February 1960
Angiology;Feb1960 Part 1, Vol. 11 Issue 1, p31
Academic Journal
SU-3118 was administered to ,56, principally male, outpatient hypertensives and was found to have significant, albeit on the average slight, antihypertensive action in approximately two-fifths of patients in doses up to 12 mg daily. About two-fifths of reserpine responders were noted to respond to this drug and side effects were about one-third to one-half as frequent with SU-3118 as with reserpine, SU-3118 appears to be less than one-seventh as potent as its parent drug.


Related Articles

  • Sensitive Adsorption Stripping Voltammetric Determination of Reserpine by a Glassy Carbon Electrode Modified with Multi-Wall Carbon Nanotubes. Huajie Zhang; Kangbing Wu // Microchimica Acta;Feb2005, Vol. 149 Issue 1/2, p73 

    Adsorption stripping voltammetry, a very sensitive electroanalytical method, was employed to determine reserpine, a kind of anti-hypertensive drug. In 0.1?M phosphate buffer with a pH of 6.0, reserpine was accumulated at a multi-wall carbon nanotubes (MWNT)-modified glassy carbon electrode (GCE)...

  • Antihypertensives. Cranwell-Bruce, Lisa A. // MEDSURG Nursing;Oct2008, Vol. 17 Issue 5, p337 

    The article examines different classes of drugs which are used in treating hypertension as well as their side effects. It offers considerations on the drugs' pharmacotherapeutics and pharmacodynamics effect as well as considerations about hypertension, which is defined as the constant increased...

  • LONG-TERM ADMINISTRATION OF RESERPINE IN HYPERTENSION. Kert, Morley J.; Penzell, Yale; Nordyke, Robert A.; Roth, Samuel I.; Smith, L. Allen; Westergart, Jack // Angiology;Oct1957, Vol. 8 Issue 5, p466 

    Reserpine was administered to a group of 79 out-patients with moderate to severe hypertension for as long as 34 months. Sixty per cent exhibited a significant fall in blood pressure and approximately 21 per cent of the entire group became normotensive. There were no serious toxic reactions but...

  • RAUWOLFIA ALKALOIDS. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2010, p720 

    The article presents information on rauwolfia alkaloids, which are antihypertensive drugs, including their dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • Treatment for two types of hypertension.  // Clinical Advisor;Jan2014, Vol. 17 Issue 1, p36 

    The article evaluates the Adempas tablets for hypertension treatment from Bayer HealthCare Co. Ltd.

  • Potential Drug - Drug Interactions among Medications Prescribed to Hypertensive Patients. KOTHARI, NITIN; GANGULY, BARNA // Journal of Clinical & Diagnostic Research;Nov2014, Vol. 8 Issue 11, p1 

    Context: Drug-drug interactions(DDIs) are significant but avoidable causes of iatrogenic morbidity and hospital admission. Aim: To detect potential drug-drug interactions among medications received by hypertensive patients. Materials and Methods: Patients of both sex and all adult age groups,...

  • ACETAZOLAMIDE ALONE AND IN COMBINATION WITH RESERPINE IN THE TREATMENT OF HYPERTENSION. Brest, Albert N.; Onesti, Gaddo; Sekine, George; Kodama, Ryuichi; Moyer, John H. // Angiology;Nov1961, Vol. 12 Issue 11, p589 

    Acetazolamide used alone produced a minor antihypertensive effect. Although the addition of reserpine enhanced the hypotensive response, the therapeutic combination of acetazolamide and reserpine appears to be less effective than combined thiazide-Rauwolfia regimens. The antihypertensive...

  • Once-daily oral therapy for hypertension available.  // Clinical Advisor;May2011, Vol. 14 Issue 5, p33 

    The article offers information on Edarbi, an oral therapy for hypertension, from Takeda Pharmaceuticals North America, and its proper administration. It states that it can treat hypertension with the azilsartan blocking the vasoconstrictor and aldosterone -secreting effects of angiotensin II. It...

  • Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones. Haas, Wolfgang; Sanfilippo, Christine M.; Hesje, Christine K.; Morris, Timothy W. // Clinical Ophthalmology;May2013, Vol. 7, p821 

    Introduction: Previous work has shown that besifloxacin, an 8-chloro-fluoroquinolone, has more potent activity against gram-positive pathogens than moxifloxacin and gatifloxacin, which carry an 8-methoxy group. This study was conducted to determine the contribution of the R7 and R8 substituent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics